Last updated on March 2019

Exploring the Safety and Tolerability of Conversion From Oral or Injectable Disease Modifying Therapies to Dose-titrated Oral Siponimod in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi-Center Phase IIIb Study

Brief description of study

To assess early phase safety and tolerability of converting patients from approved oral and injectable RMS DMTs to siponimod.

The results of this study will guide clinically relevant decisions related to the transition from frequently used RMS DMTs to siponimod and provide clinically relevant data on safety and tolerability for healthcare providers who are considering converting patients from currently approved RMS DMT to siponimod.


Clinical Study Identifier: TX218143

Find a site near you

Start Over